That statistic comes from a trial of women aged 65 and older given one particular oral hormone regimen, not from women who start hormone therapy around the time of menopause.

In that older group, combined estrogen-progestin roughly doubled the rate of probable dementia, but in absolute terms that was 23 extra cases per 10,000 women per year. Trials in women who started therapy in their early 50s found no increase in dementia or cognitive harm. The doubling statistic is real, but it does not apply to the age group that typically starts hormone therapy today.

What to know about this answer

The dementia-doubling statistic is accurate for its own trial population but is often quoted without saying who was studied. The real debate is whether that finding says anything about the much larger group of women who start hormone therapy in their late 40s and 50s.

What the research shows, and which source each finding rests on

WHIMS found that oral CEE plus MPA in women 65 or older doubled the rate of probable dementia versus placebo (hazard ratio 2.05), an absolute excess of 23 cases per 10,000 women per year.

B[1]

A meta-analysis of randomized trials confirms increased dementia risk with hormone therapy in women 65 and older (RR 1.38), driven by estrogen plus progestogen, with no significant effect from estrogen-only.

A[2]

Trials that enrolled recently postmenopausal women (KEEPS-Cog, ELITE, WHIMSY) found no cognitive harm from hormone therapy started around the time of menopause.

B[3]B[4]B[5]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

the warning was over-extrapolated to younger women

Sharon Malone, Rachel Rubin, and the FDA's own November 2025 reasoning

The dementia finding came from women who were on average about 15 years past menopause, given one oral regimen for the first time; the FDA concluded this population does not represent the typical hormone therapy starter (roughly ages 45 to 55).

E[6]

the underlying trial finding at 65-plus is real and should not be dismissed

the WHIMS investigators and guideline bodies

The hazard ratio was statistically significant and consistent across the estrogen-plus-progestin and pooled estrogen-alone analyses, and remains a reason guidelines caution against starting hormone therapy for the first time at older ages.

B[1]

What would settle it: A trial of women who start hormone therapy at younger ages, followed long enough and with sensitive enough measures to detect a real dementia signal if one exists.

What is really going on here

  1. Was the dementia warning based on women like me?
  2. Is the number I'm hearing a relative risk or an absolute risk?
  3. Which formulation and route does this specific finding cover?

Questions for your doctor

  1. How does my age and years since menopause affect this specific risk?
  2. Is the regimen being discussed with me the same one studied in that trial, or a different formulation?
  3. What is my absolute added risk, in real numbers, rather than a percentage?
  4. Does starting later change the calculation for me specifically?

Questions with no answer yet

Would the same doubled-risk finding show up if the trial had enrolled women in their early 50s instead of women who were, on average, about 15 years past menopause?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The doubling of dementia risk was found only in women 65 and older on one oral regimen. Trials that enrolled recently postmenopausal women found no cognitive harm, but no trial has specifically re-tested the dementia diagnosis endpoint itself in younger starters.

What would test it: A dementia-endpoint trial, not just a cognitive-test-score trial, in women who start therapy in their late 40s to 50s, followed long enough to observe diagnoses.

Is the underlying hazard truly tied to starting late in life, or could a similarly aged brain be equally vulnerable regardless of when a woman first took hormone therapy?

Partly studied

What is known: The trial population was uniformly older at first exposure, so age at first use and age at outcome measurement were never separated. The timing hypothesis assumes a critical window, but this has not been directly tested for the dementia endpoint itself.

What would test it: A trial or large cohort comparing women who start hormone therapy late in life against women who started earlier and continued into the same older age bracket.

Sources

  1. 1.Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.Shumaker SA et al. (WHIMS), JAMA 2003 · Randomised trial
  2. 2.Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer's disease and dementia.Nerattini M et al., Front Aging Neurosci 2023 · Systematic review or guideline
  3. 3.Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study.Gleason CE et al. (KEEPS-Cog), PLoS Med 2015 · Randomised trial
  4. 4.Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis.Henderson VW et al. (ELITE), Neurology 2016 · Randomised trial
  5. 5.Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years.Espeland MA et al. (WHIMSY), JAMA Intern Med 2013 · Randomised trial
  6. 6.FDA press announcement on menopausal hormone therapy labeling changes, November 2025Review, opinion or mechanism

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions